Z6尊龙
Other Affiliated Sites
Techdow Pharma China
Techdow Pharma UK
Techdow Pharma Poland
Techdow Pharma Italy
Techdow Pharma Spain
Techdow Pharma Germany
Techdow Pharma US
Cytovance Biologics
SPL
Simplified Chinese
Traditional Chinese
About Hepalink
Group Profile
Corporate Philosophy
Milestones
Leadership Team
Scientific Advisory Board
Our Businesses
Heparin Business
Global Industrial Chain
Global Heparin Injections Business
Product Profile
CDMO Services
Innovative Drugs
Global Manufacturing
Company News
Investor Relations
Corporate Governance
Disclosures
Stock Information
IR Events
IR Contact
Join Us
Career Development
Job Opportunities
Campus Recruitment
Contact Us
Create Value for Investors Through
Safe and Stable Operations
Corporate Governance
Disclosures
Stock Information
IR Events
IR Contact
Disclosures
A-Share Information
H-Share Information
Financial Reports
Announcements
2024.03.29
Z6尊龙:关于使用自有资金购置理工业品及举行现金治理的通告
2024.03.29
Z6尊龙:关于开展以套期保值为目的的外汇衍生品生意的通告
2024.03.29
Z6尊龙:关于公司2023年计提资产减值准备的通告
2024.03.29
Z6尊龙:关于自力第三方视察效果的通告
2024.03.29
Z6尊龙:关于2024年度向银行申请授信额度暨提供担保的通告
2024.03.29
Z6尊龙:第六届董事会第九次聚会决议通告
2024.03.29
Z6尊龙:2023年年度股东大会通知
2024.03.29
Z6尊龙:2023年年度报告摘要
2024.03.15
Z6尊龙:关于收到现实控制人先行垫付款子的通告
2024.02.05
Z6尊龙:关于深圳证监局对公司接纳责令纠正步伐决议的通告
第一页
上一页
1
2
3
4
5
下一页
最后一页
About Hepalink
Group Profile
Corporate Philosophy
Milestones
Leadership Team
Scientific Advisory Board
Our Businesses
Heparin Business
CDMO Services
Innovative Drugs
Global Manufacturing
Company News
Investor Relations
Corporate Governance
Disclosures
Stock Information
IR Events
IR Contact
Join Us
Career Development
Job Opportunities
Campus Recruitment
Contact Us
Official WeChat Account
Legal Statement
·
Environmental Disclosure
Copyright ? 2024 Hepalink Group. All Rights Reserved.
【网站地图】
【sitemap】